-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, the company's holding subsidiary Henan Zhongshuai Pharmaceutical Technology Co., Ltd. (“Zhongshuai Pharmaceutical”) received the “Drug GMP Compliance Inspection Notice” issued by the Henan Drug Administration. Production type: acetazolamide extended-release capsules (specification: 0.5g, Sinopharm standard H20265455); workshop, production line: solid preparation workshop, capsule production line passed this drug GMP compliance inspection. Acetazolamide extended-release capsules are the first domestic drug approved to prevent or ameliorate acute mountain sickness. They were approved for sale in August 2026 and have yet to be marketed.
Share
Listen to the news
Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, the company's holding subsidiary Henan Zhongshuai Pharmaceutical Technology Co., Ltd. (“Zhongshuai Pharmaceutical”) received the “Drug GMP Compliance Inspection Notice” issued by the Henan Drug Administration. Production type: acetazolamide extended-release capsules (specification: 0.5g, Sinopharm standard H20265455); workshop, production line: solid preparation workshop, capsule production line passed this drug GMP compliance inspection. Acetazolamide extended-release capsules are the first domestic drug approved to prevent or ameliorate acute mountain sickness. They were approved for sale in August 2026 and have yet to be marketed.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending